Psoriasis Clinical Trials in Portland
View 30 new treatments for Psoriasis in Portland, OR, and nearby areas, such as Gresham. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Scalp Psoriasis
Bristol-Myers Squibb Clinic, Portland + 2 more
This trial is testing a medication called deucravacitinib to see if it can help people with moderate-to-severe scalp psoriasis. The medication works by blocking proteins that cause inflammation and immune responses, which are responsible for the red, itchy, and scaly patches on the scalp. The goal is to find out if this treatment is safe and effective.Show More
Waitlist
Phase 4
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Chair
Subcutaneous Risankizumab for Psoriasis
AbbVie Clinic, Portland + 2 more
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 4
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Portland + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Portland + 2 more
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
ESK-001 for Psoriasis
Alumis Clinic, Portland + 1 more
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Apremilast for Pediatric Plaque Psoriasis
Amgen Clinic, Portland + 1 more
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Portland + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Secukinumab for Juvenile Arthritis
Novartis Clinic, Portland + 3 more
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Novartis Pharmaceuticals
Study Director
Tapinarof Cream for Plaque Psoriasis
Dermavant Sciences Clinic, Portland + 1 more
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Diana Villalobos
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Portland + 4 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions